The financials
Nuvation Bio Inc. by the numbers
Nuvation Bio Inc. (NUVB) reported revenue of $83M in Q1 2026 (quarter ended March 31, 2026), up 2599% from the same quarter a year earlier. That came with net income of $5.4M (6.5% of revenue). For the full year FY2025, revenue was $63M (+699% year on year) and net income −$205M. Its largest product in 2026-Q1 was License at $65M, 76% of the disclosed total, just ahead of Product at 22%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $83M | $3.1M | +2599% |
| Gross profit | n/a | $990K | n/a |
| Operating income | $3.9M | −$59M | to a profit |
| Net income | $5.4M | −$53M | to a profit |
| Diluted EPS | $0.01 | −$0.16 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| License | $65M | 76% |
| Product | $19M | 22% |
| Royalty | $1.4M | 1.6% |
| Research And Development Service | $700K | 0.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $85.3M (+458%)
Product grew +2275% year on yearResearch And Development Service -66% year on year
Segment Latestquarter on quarteryear on year
- License$64.7M$64.7MQoQ +1099%year on year +1999%+1099%+1999%
- Product$18.5M$18.5MQoQ +140%year on year +2275%+140%+2275%
- Royalty$1.4M$1.4MQoQ +367%year on year +462%+367%+462%
- Research And Development Service$700.0K$700.0KQoQ -63%year on year -66%-63%-66%